The use of infliximab leads to the restoration of the ability of T regulatory cells in patients with autoimmune diseases to inhibit the production of pro-inflammatory mediators TNF and IFN-γ by activated T cells and monocytes, and to induce the formation of an immunosuppressive phenotype of CD4+ CD25+ T cells [250]. The gene discussed is TNF; the disease is autoimmune disease.